Related references
Note: Only part of the references are listed.Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer
Arcadi Cipponi et al.
SCIENCE (2020)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death
Rabea Oberthuer et al.
CANCER LETTERS (2017)
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
Rachel Thijssen et al.
BLOOD (2016)
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
Martin Schuler et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer The ASPIRATION Study
Keunchil Park et al.
JAMA ONCOLOGY (2016)
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
C. Zhou et al.
ANNALS OF ONCOLOGY (2015)
Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response
Hong-Jen Lee et al.
CELL RESEARCH (2015)
Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage
Gianmaria Liccardi et al.
CLINICAL CANCER RESEARCH (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM-Defective Tumors
Arina Riabinska et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
DNA-PK is a DNA sensor for IRF-3-dependent innate immunity
Brian J. Ferguson et al.
ELIFE (2012)
EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment
Gianmaria Liccardi et al.
CANCER RESEARCH (2011)
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2011)
Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells
Wei-Chien Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Concordant and opposite roles of DNA-PK and the facilitator of chromatin transcription (FACT) in DNA repair, apoptosis and necrosis after cisplatin
Janna Sand-Dejmek et al.
MOLECULAR CANCER (2011)
More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance
Jiri Lukas et al.
NATURE CELL BIOLOGY (2011)
The DNA Damage Response: Making It Safe to Play with Knives
Alberto Ciccia et al.
MOLECULAR CELL (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The DNA-damage response in human biology and disease
Stephen P. Jackson et al.
NATURE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK
Klaus Dittmann et al.
MOLECULAR CANCER (2008)
DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs
ET Shinohara et al.
CANCER RESEARCH (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
DNA double-strand breaks: signaling, repair and the cancer connection
KK Khanna et al.
NATURE GENETICS (2001)
DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA
WM Chu et al.
CELL (2000)
Share Paper
